/주식/MNPR
MNPR

MNPR

USD

Monopar Therapeutics Inc. Common Stock

$82.710-3.240 (-3.770%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$85.950

고가

$86.140

저가

$80.105

거래량

0.14M

기업 기본 정보

시가총액

510.3M

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.07M

거래소

NCM

통화

USD

52주 범위

저가 $14.877현재가 $82.710고가 $105

관련 뉴스

Analyst Upgrades

Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics with a Overweight rating and announces Price Target of $125.

더 보기
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
Analyst Upgrades

Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142

Raymond James analyst Chris Raymond maintains Monopar Therapeutics with a Strong Buy and raises the price target from $80 to $142.

더 보기
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics with a Buy and raises the price target from $70 to $105.

더 보기
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105
Analyst Upgrades

Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics with a Overweight and raises the price target from $76 to $95.

더 보기
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95
Analyst Upgrades

Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics with a Buy and raises the price target from $60 to $85.

더 보기
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85
Analyst Upgrades

BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics with a Buy and raises the price target from $87 to $104.

GlobeNewswire

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics", "Monopar", or the "Company"), a clinical-stage biopharmaceutical company developing innovative

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기